Atopic dermatitis (AD) is the most common chronic inflammatory skin disease in man, with a lifetime prevalence of up to 20%. Leading symptoms include i.a. agonizing pruritus and recurrent eczematous skin lesions. Modulation of the JAK-STAT signaling pathway with oral JAK inhibitors (JAKIs) is a novel therapeutic option. We report the case of a 62-year-old Caucasian patient with severe AD with comorbidity of ankylosing spondylitis and recurrent uveitis who is in sustained remission of both AD and comorbidities after receiving oral upadacitinib therapy.